metoprolol has been researched along with Auricular Flutter in 12 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded "seamless" phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF)." | 9.27 | A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. ( Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB, 2018) |
| "Diltiazem (calcium channel blocker) and metoprolol (beta-blocker) are both commonly used to treat atrial fibrillation/flutter (AFF) in the emergency department (ED)." | 9.20 | Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department. ( Cohen, V; Fromm, C; Jellinek-Cohen, S; Likourezos, A; Marshall, J; Rose, J; Suau, SJ, 2015) |
| "Ibutilide is a type III antiarrhythmic agent approved for the pharmacologic conversion of atrial fibrillation (AF) and atrial flutter (AFl)." | 9.12 | Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter. ( McPherson, CA; Mountantonakis, SE; Moutzouris, DA; Papaioannou, GN; Tiu, RV, 2006) |
| "To assess the effectiveness of metoprolol in preventing clinically detectable atrial fibrillation (AF) and flutter after coronary artery bypass graft (CABG) surgery." | 9.11 | Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery. ( Blacher, C; Flores, A; Leães, PE; Lucchese, FA; Lúcio, Ede A; Ribeiro, JP, 2004) |
| "The antiarrhythmic effect of the cardioselective beta-adrenoreceptor blocking agent metoprolol, given intravenously, was studied in 20 patients with acute supraventricular tachyarrhythmias, including patients with congestive heart failure, acute myocardial infarction and complete bundle branch block." | 7.66 | Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias. ( Kesteloot, H; Stroobandt, R, 1981) |
| " One observation study showed no difference between metoprolol and diltiazem for successful rate control, but worsening heart failure symptoms occurred more frequently in those receiving diltiazem compared to metoprolol (19 patients [33%] vs." | 5.41 | Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. ( Balhara, KS; Ehmann, MR; Hinson, JS; Lobner, K; Niforatos, JD; Ramcharran, L; Weygandt, PL, 2023) |
| "The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded "seamless" phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF)." | 5.27 | A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. ( Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB, 2018) |
| "Diltiazem (calcium channel blocker) and metoprolol (beta-blocker) are both commonly used to treat atrial fibrillation/flutter (AFF) in the emergency department (ED)." | 5.20 | Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department. ( Cohen, V; Fromm, C; Jellinek-Cohen, S; Likourezos, A; Marshall, J; Rose, J; Suau, SJ, 2015) |
| "Ibutilide is a type III antiarrhythmic agent approved for the pharmacologic conversion of atrial fibrillation (AF) and atrial flutter (AFl)." | 5.12 | Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter. ( McPherson, CA; Mountantonakis, SE; Moutzouris, DA; Papaioannou, GN; Tiu, RV, 2006) |
| "To assess the effectiveness of metoprolol in preventing clinically detectable atrial fibrillation (AF) and flutter after coronary artery bypass graft (CABG) surgery." | 5.11 | Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery. ( Blacher, C; Flores, A; Leães, PE; Lucchese, FA; Lúcio, Ede A; Ribeiro, JP, 2004) |
| "The antiarrhythmic effect of the cardioselective beta-adrenoreceptor blocking agent metoprolol, given intravenously, was studied in 20 patients with acute supraventricular tachyarrhythmias, including patients with congestive heart failure, acute myocardial infarction and complete bundle branch block." | 3.66 | Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias. ( Kesteloot, H; Stroobandt, R, 1981) |
| "Twenty one patients with either paroxysmal supraventricular tachycardia (group A), atrial flutter (group B), or atrial fibrillation (group C) were treated with intravenous metoprolol in the dose range 2--20 mg." | 3.66 | Metoprolol in the treatment of supraventricular tachyarrhythmias. ( Möller, B; Ringqvist, C, 1979) |
| "Hypotension is an important potential side effect." | 2.67 | Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. ( Amsterdam, EA; Kulcyski, J; Ridgeway, MG, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Niforatos, JD | 1 |
| Ehmann, MR | 1 |
| Balhara, KS | 1 |
| Hinson, JS | 1 |
| Ramcharran, L | 1 |
| Lobner, K | 1 |
| Weygandt, PL | 1 |
| Piccini, JP | 1 |
| Connolly, SJ | 1 |
| Abraham, WT | 1 |
| Healey, JS | 1 |
| Steinberg, BA | 1 |
| Al-Khalidi, HR | 1 |
| Dignacco, P | 1 |
| van Veldhuisen, DJ | 2 |
| Sauer, WH | 1 |
| White, M | 1 |
| Wilton, SB | 1 |
| Anand, IS | 1 |
| Dufton, C | 1 |
| Marshall, DA | 1 |
| Aleong, RG | 1 |
| Davis, GW | 1 |
| Clark, RL | 1 |
| Emery, LL | 1 |
| Bristow, MR | 1 |
| Fromm, C | 1 |
| Suau, SJ | 1 |
| Cohen, V | 1 |
| Likourezos, A | 1 |
| Jellinek-Cohen, S | 1 |
| Rose, J | 1 |
| Marshall, J | 1 |
| Lúcio, Ede A | 1 |
| Flores, A | 1 |
| Blacher, C | 1 |
| Leães, PE | 1 |
| Lucchese, FA | 1 |
| Ribeiro, JP | 1 |
| Wiesfeld, AC | 1 |
| Ansink, JM | 1 |
| van Gelder, IC | 1 |
| Mountantonakis, SE | 1 |
| Moutzouris, DA | 1 |
| Tiu, RV | 1 |
| Papaioannou, GN | 1 |
| McPherson, CA | 1 |
| Stroobandt, R | 1 |
| Kesteloot, H | 1 |
| Rehnqvist, N | 1 |
| Frost, L | 1 |
| Mølgaard, H | 1 |
| Christiansen, EH | 1 |
| Jacobsen, CJ | 1 |
| Pilegaard, H | 1 |
| Thomsen, PE | 1 |
| Möller, B | 1 |
| Ringqvist, C | 1 |
| Amsterdam, EA | 1 |
| Kulcyski, J | 1 |
| Ridgeway, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure[NCT01970501] | Phase 2 | 267 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with adequate ventricular rate control following the start of medication during the 24-week Follow-up Period (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Bucindolol Hydrochloride | 84 |
| Metoprolol Succinate | 116 |
Time-to-event is calculated as the date of the event minus the date of initiation of efficacy follow-up, with 1 added in order to include both the start date and end date of the interval. Cox's proportional hazards model will be used to calculate estimated hazard ratios and 95% confidence intervals. The calculations will be performed with the SAS PHREG procedure, with the stratification variables specified in the STRATA statement and the treatment group comparator and any covariates being examined specified in the MODEL statement. For the primary endpoint, the appropriateness of assuming proportional hazards will be explored by the graphing of log (-log(survival function)) over follow-up for each treatment group. (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | days (Mean) |
|---|---|
| Bucindolol Hydrochloride | 35.9 |
| Metoprolol Succinate | 33.2 |
Number of days on study medication before participant experienced symptomatic or asymptomatic atrial fibrillation, atrial flutter, or all-cause mortality during the 24 week follow up period. (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | days (Mean) |
|---|---|
| Bucindolol Hydrochloride | 37.86 |
| Metoprolol Succinate | 31.06 |
Total number of hospitalization days per patient (all-cause) following the start of study medication during the Total Study Period (24 weeks). Hospitalization was defined by a hospital admission (note that same day admit and discharge equates to 0 days duration), ER visits were not counted as events. (NCT01970501)
Timeframe: 24 weeks
| Intervention | days (Median) |
|---|---|
| Bucindolol Hydrochloride | 2 |
| Metoprolol Succinate | 2 |
1 review available for metoprolol and Auricular Flutter
| Article | Year |
|---|---|
Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Diltiazem; Heart Failure; Humans | 2023 |
6 trials available for metoprolol and Auricular Flutter
| Article | Year |
|---|---|
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2018 |
Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Diltiazem; Double | 2015 |
Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Case-Control Studies; Coronary Ar | 2004 |
Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Emergency Service, Hospital; Fema | 2006 |
Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Clinical Trials | 1981 |
Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Female; Humans; Hypotension; In | 1991 |
5 other studies available for metoprolol and Auricular Flutter
| Article | Year |
|---|---|
ECG Response: August 4, 2015.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Female; Humans; Metoprolol; Trea | 2015 |
Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia?
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Thera | 2006 |
Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Female; Humans; Injections, Intravenous; Male; Metoprolol | 1981 |
Atrial ectopic activity and atrial fibrillation/flutter after coronary artery bypass surgery. A case-base study controlling for confounding from age, beta-blocker treatment, and time distance from operation.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atrial Fibrillation; Atrial Flutter; Autonomi | 1995 |
Metoprolol in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Drug Evaluation; Female; Heart Rat | 1979 |